V16 Stock Overview
Manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for V16 from our risk checks.
Virbac SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €379.50 |
| 52 Week High | €392.00 |
| 52 Week Low | €248.50 |
| Beta | 0.95 |
| 11 Month Change | 5.42% |
| 3 Month Change | 8.27% |
| 1 Year Change | 43.21% |
| 33 Year Change | 5.42% |
| 5 Year Change | 64.64% |
| Change since IPO | 249.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| V16 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.5% | -3.9% | 0.02% |
| 1Y | 43.2% | -15.4% | 11.7% |
Return vs Industry: V16 exceeded the German Pharmaceuticals industry which returned -15.4% over the past year.
Return vs Market: V16 exceeded the German Market which returned 11.7% over the past year.
Price Volatility
| V16 volatility | |
|---|---|
| V16 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V16 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: V16's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 5,459 | Habib Ramdani | corporate.virbac.com |
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners.
Virbac SA Fundamentals Summary
| V16 fundamental statistics | |
|---|---|
| Market cap | €3.22b |
| Earnings (TTM) | €141.19m |
| Revenue (TTM) | €1.34b |
22.8x
P/E Ratio2.4x
P/S RatioIs V16 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V16 income statement (TTM) | |
|---|---|
| Revenue | €1.34b |
| Cost of Revenue | €446.54m |
| Gross Profit | €892.83m |
| Other Expenses | €751.63m |
| Earnings | €141.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.86 |
| Gross Margin | 66.66% |
| Net Profit Margin | 10.54% |
| Debt/Equity Ratio | 37.2% |
How did V16 perform over the long term?
See historical performance and comparison